{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=TNBC%2C+Triple+Negative+Breast+Cancer&page=3", "query": { "condition": "TNBC, Triple Negative Breast Cancer", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 654, "total_pages": 66, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=TNBC%2C+Triple+Negative+Breast+Cancer&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=TNBC%2C+Triple+Negative+Breast+Cancer&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T16:19:11.359Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06238921", "title": "Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Stereotactic Radiation", "type": "RADIATION" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Sacituzumab govitecan", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2024-12-19", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2025-12-05", "last_synced_at": "2026-10-04T16:19:11.359Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06238921" }, { "nct_id": "NCT01238133", "title": "Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Estrogen Receptor Negative", "HER2/Neu Negative", "Progesterone Receptor Negative", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gamma-Secretase Inhibitor RO4929097", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2010-12", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2015-09-04", "last_synced_at": "2026-10-04T16:19:11.359Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01238133" }, { "nct_id": "NCT03609671", "title": "Emotions Immunology and Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Triple Negative Breast Cancer", "Emotions", "Immunology" ], "interventions": [ { "name": "Standard of Care + Experimental Individualized Therapy", "type": "BEHAVIORAL" }, { "name": "Control: Standard of Care", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Luz A. Venta, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 17, "start_date": "2015-11-23", "completion_date": "2019-03-18", "has_results": false, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-10-04T16:19:11.359Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03609671" }, { "nct_id": "NCT03961698", "title": "Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Renal Cell Carcinoma" ], "interventions": [ { "name": "IPI-549 (eganelisib)", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Infinity Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2019-12-17", "completion_date": "2023-08-31", "has_results": false, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-10-04T16:19:11.359Z", "location_count": 24, "location_summary": "Chandler, Arizona • Tucson, Arizona • Fullerton, California + 20 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03961698" }, { "nct_id": "NCT02554812", "title": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Utomilumab", "type": "DRUG" }, { "name": "PF-04518600", "type": "DRUG" }, { "name": "PD 0360324", "type": "DRUG" }, { "name": "CMP-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 409, "start_date": "2015-11-09", "completion_date": "2023-03-23", "has_results": true, "last_update_posted_date": "2024-07-30", "last_synced_at": "2026-10-04T16:19:11.359Z", "location_count": 57, "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 23 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02554812" }, { "nct_id": "NCT05081492", "title": "CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Triple-Negative Breast Carcinoma", "Prognostic Stage IV Breast Cancer AJCC v8" ], "interventions": [ { "name": "Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2021-10-18", "completion_date": "2027-03-01", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-10-04T16:19:11.359Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05081492" }, { "nct_id": "NCT02950064", "title": "A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Neoplasms", "Ovarian Neoplasms", "Breast Neoplasms", "Prostatic Neoplasms" ], "interventions": [ { "name": "BTP-114", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Placon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2016-09", "completion_date": "2020-08", "has_results": false, "last_update_posted_date": "2019-01-14", "last_synced_at": "2026-10-04T16:19:11.359Z", "location_count": 8, "location_summary": "Sarasota, Florida • Boston, Massachusetts • St Louis, Missouri + 4 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02950064" }, { "nct_id": "NCT02593175", "title": "Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage I Breast Cancer AJCC v7", "Stage IA Breast Cancer AJCC v7", "Stage IB Breast Cancer AJCC v7", "Stage II Breast Cancer AJCC v6 and v7", "Stage IIA Breast Cancer AJCC v6 and v7", "Stage IIB Breast Cancer AJCC v6 and v7", "Stage III Breast Cancer AJCC v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Panitumumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2016-11-03", "completion_date": "2025-04-03", "has_results": true, "last_update_posted_date": "2025-11-06", "last_synced_at": "2026-10-04T16:19:11.359Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02593175" }, { "nct_id": "NCT03310957", "title": "Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Triple Negative Breast Neoplasms" ], "interventions": [ { "name": "ladiratuzumab vedotin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 185, "start_date": "2018-02-27", "completion_date": "2024-09-30", "has_results": true, "last_update_posted_date": "2025-12-12", "last_synced_at": "2026-10-04T16:19:11.359Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03310957" }, { "nct_id": "NCT06545331", "title": "Study of XB010 in Subjects With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced or Metastatic Solid Tumors", "Esophageal Squamous Cell Cancer", "Head and Neck Squamous Cell Cancer", "NSCLC (Non-small Cell Lung Cancer)", "Hormone-receptor-positive Breast Cancer", "Triple Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "XB010", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 396, "start_date": "2024-08-06", "completion_date": "2027-10-20", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-10-04T16:19:11.359Z", "location_count": 16, "location_summary": "Irvine, California • Los Angeles, California • Washington D.C., District of Columbia + 12 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06545331" } ] }